Cargando…
Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer
PURPOSE: L-type amino acid transporter 1 (LAT1), a Na(+)-independent amino acid transporter, is highly expressed in various cancer types. We evaluated the prognostic value of LAT1 expression in non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively reviewed 119 consecut...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387640/ https://www.ncbi.nlm.nih.gov/pubmed/34458203 http://dx.doi.org/10.2147/RRU.S326249 |
_version_ | 1783742482221105152 |
---|---|
author | Sawazaki, Harutake Arai, Yuichi Ito, Yuji Sato, Kimiya Tsuda, Hitoshi Yamaga, Takashi Sakurai, Hiroyuki |
author_facet | Sawazaki, Harutake Arai, Yuichi Ito, Yuji Sato, Kimiya Tsuda, Hitoshi Yamaga, Takashi Sakurai, Hiroyuki |
author_sort | Sawazaki, Harutake |
collection | PubMed |
description | PURPOSE: L-type amino acid transporter 1 (LAT1), a Na(+)-independent amino acid transporter, is highly expressed in various cancer types. We evaluated the prognostic value of LAT1 expression in non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively reviewed 119 consecutive patients who underwent initial transurethral resection of bladder tumor. Of these, 75 patients with NMIBC were included in this study. Patients were classified into two groups according to the proportion of LAT1-positive cells, as determined by immunohistochemistry. Associations between LAT1 expression and clinicopathological factors were analyzed. Cox multivariate analyses were performed to identify independent predictors of intravesical recurrence (IVR). The LAT1 integrated risk model was compared with the European Organization for Research and Treatment of Cancer (EORTC) risk model to evaluate the predictive ability for IVR based on the c-index. RESULTS: The median follow-up was 37 months. Twenty-eight patients (37.3%) had IVR. LAT1 expression was not correlated with any other clinicopathological factors. Patients with high LAT1 expression had a worse IVR-free survival than that of patients with low LAT1 expression (P = 0.038). Cox multivariate analyses indicated that tumor multiplicity and high LAT1 expression were independent predictors of IVR. The LAT1 integrated risk model had a significantly improved performance over the EORTC model for assessing recurrence risk (c-index: 0.695, improvement: 0.091, P = 0.001). When patients were stratified into three groups according to the score calculated by the LAT1 integrated risk model, the 2-year IVR-free survival rates were 93.3% in patients with 0 points, 66.9% for those with 2 points, and 37.5% for those with 4 points. CONCLUSION: High LAT1 expression was an independent predictor of IVR in patients with NMIBC. The LAT1 integrated risk model had good predictability for IVR. |
format | Online Article Text |
id | pubmed-8387640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83876402021-08-26 Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer Sawazaki, Harutake Arai, Yuichi Ito, Yuji Sato, Kimiya Tsuda, Hitoshi Yamaga, Takashi Sakurai, Hiroyuki Res Rep Urol Original Research PURPOSE: L-type amino acid transporter 1 (LAT1), a Na(+)-independent amino acid transporter, is highly expressed in various cancer types. We evaluated the prognostic value of LAT1 expression in non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively reviewed 119 consecutive patients who underwent initial transurethral resection of bladder tumor. Of these, 75 patients with NMIBC were included in this study. Patients were classified into two groups according to the proportion of LAT1-positive cells, as determined by immunohistochemistry. Associations between LAT1 expression and clinicopathological factors were analyzed. Cox multivariate analyses were performed to identify independent predictors of intravesical recurrence (IVR). The LAT1 integrated risk model was compared with the European Organization for Research and Treatment of Cancer (EORTC) risk model to evaluate the predictive ability for IVR based on the c-index. RESULTS: The median follow-up was 37 months. Twenty-eight patients (37.3%) had IVR. LAT1 expression was not correlated with any other clinicopathological factors. Patients with high LAT1 expression had a worse IVR-free survival than that of patients with low LAT1 expression (P = 0.038). Cox multivariate analyses indicated that tumor multiplicity and high LAT1 expression were independent predictors of IVR. The LAT1 integrated risk model had a significantly improved performance over the EORTC model for assessing recurrence risk (c-index: 0.695, improvement: 0.091, P = 0.001). When patients were stratified into three groups according to the score calculated by the LAT1 integrated risk model, the 2-year IVR-free survival rates were 93.3% in patients with 0 points, 66.9% for those with 2 points, and 37.5% for those with 4 points. CONCLUSION: High LAT1 expression was an independent predictor of IVR in patients with NMIBC. The LAT1 integrated risk model had good predictability for IVR. Dove 2021-08-21 /pmc/articles/PMC8387640/ /pubmed/34458203 http://dx.doi.org/10.2147/RRU.S326249 Text en © 2021 Sawazaki et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sawazaki, Harutake Arai, Yuichi Ito, Yuji Sato, Kimiya Tsuda, Hitoshi Yamaga, Takashi Sakurai, Hiroyuki Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title | Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title_full | Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title_fullStr | Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title_full_unstemmed | Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title_short | Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer |
title_sort | expression of l-type amino acid transporter 1 is a predictive biomarker of intravesical recurrence in patients with non-muscle invasive bladder cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387640/ https://www.ncbi.nlm.nih.gov/pubmed/34458203 http://dx.doi.org/10.2147/RRU.S326249 |
work_keys_str_mv | AT sawazakiharutake expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT araiyuichi expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT itoyuji expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT satokimiya expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT tsudahitoshi expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT yamagatakashi expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer AT sakuraihiroyuki expressionofltypeaminoacidtransporter1isapredictivebiomarkerofintravesicalrecurrenceinpatientswithnonmuscleinvasivebladdercancer |